Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2012; 18(43): 6183-6188
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6183
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6183
Figure 2 The outcome of the three landmark trials for boceprevir-based triple therapy in hepatitis C virus genotype 1 patients.
Sustained virologic response rates are compared between groups. The SPRINT-1 and SPRINT-2 trials were conducted in treatment-naïve patients. The RESPOND-2 trial was conducted in treatment-experienced patients. B: Boceprevir; P: Peg-interferon; R: Ribavirin; The numbers (4, 24, 28 or 48): Week of treatment; SVR: Sustained virologic response; RGT: Response-guided telaprevir combination treatment.
- Citation: Pan Q, Peppelenbosch MP, Janssen HL, Knegt RJ. Telaprevir/boceprevir era: From bench to bed and back. World J Gastroenterol 2012; 18(43): 6183-6188
- URL: https://www.wjgnet.com/1007-9327/full/v18/i43/6183.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i43.6183